

EMA/215117/2019

European Medicines Agency decision

P/0152/2019

of 17 April 2019

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for voclosporin (EMA-002264-PIP01-17) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0152/2019

of 17 April 2019

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for voclosporin (EMA-002264-PIP01-17) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Aurinia Pharmaceuticals Ltd. on 12 December 2017 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 1 March 2019, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for voclosporin, capsule, soft, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for voclosporin, capsule, soft, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for voclosporin, capsule, soft, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Aurinia Pharmaceuticals Ltd., 5th Floor, 6 St. Andrew Street, EC4A 3AE – London, United Kingdom.

EMA/PDCO/903383/2019

London, 1 March 2019

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-002264-PIP01-17

Scope of the application

Active substance(s):

Voclosporin

Condition(s):

Treatment of Systemic Lupus Erythematosus

Pharmaceutical form(s):

Capsule, soft

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Aurinia Pharmaceuticals Ltd.

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Aurinia Pharmaceuticals Ltd. submitted for agreement to the European Medicines Agency on 12 December 2017 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 23 January 2018.

Supplementary information was provided by the applicant on 23 November 2018. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of Systemic Lupus Erythematosus (SLE)

The waiver applies to:

- the paediatric population from birth to less than 5 years;
- capsule, soft, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition:

Treatment of Systemic Lupus Erythematosus (SLE)

2.1.1. Indication(s) targeted by the PIP

Treatment of lupus nephritis in paediatric patients with systemic lupus erythematosus

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 5 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Capsule, soft

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable
Non-clinical studies	0	Not applicable
Clinical studies	2	Study 1 Three group and three period, adaptive design, double-blind controlled versus placebo study of pharmacokinetic, efficacy and safety of voclosporin in lupus nephritis (LN) in addition to standard therapy, in paediatric patients from 12 to less than 18 years of age with systemic lupus erythematosus (SLE); AURORA PEDS 01 (AURinia vOclosporin Renal Assessments PEDiatricS).

		Study 2 Prospective, open label, 52-week, multicentre safety study of voclosporin in addition to background standard of care with mycophenolate mofetil (MMF) and oral steroids in paediatric patients from 5 to less than 18 years of age with lupus nephritis; AURORA PEDS 02 (AURinia vOclosporin Renal Assessments PEDiatricS).
Extrapolation, modelling and simulation studies	1	Study 3 Analysis of existing in house data on voclosporin on lupus nephritis in paediatric patients to confirm whether observed paediatric data are consistent with extrapolated efficacy predictions from adults.
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By Dec 2030
Deferral for one or more measures contained in the paediatric investigation plan:	Yes